1. Pink Sheet
  2. >>R&D

COVID Collaborations: Two Ways To Define Success

 
• By Michael McCaughan

In the short term, public-private partnerships engaged in the coronavirus response will be judged on whether there are effective treatments for COVID-19. But the long-term impact may be as a test of whether collaborative models can work when the stakes are high.

Unity and teamwork concept as a business metaphor for joining a partnership as diverse ropes connected together as a corporate symbol for cooperation and working collaboration.

US National Institutes of Health Director Francis Collins is appropriately cautious in setting expectations for a new public-private partnership intended to streamline development of potential COVID-19 therapeutics and vaccines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.